Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats

Stem Cells

Volumn 25, Issue 2, 2007, Pages 385-391

  Koike, Yasushi ^a   Adachi, Yasushi ^a   Suzuki, Yasuhiro ^a   Iwasaki, Masayoshi ^a   Koike Kiriyama, Naoko ^a   Minamino, Keizo ^a   Nakano, Keiji ^a   Mukaide, Hiromi ^a   Shigematsu, Akio ^a   Kiyozuka, Yasuhiko ^a   Tubura, Airo ^a   Kamiyama, Yasuo ^a   Ikehara, Susumu ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal carcinoma; Donor lymphocyte infusion; Intrabone marrow bone marrow transplantation; Rat liver metastasis

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BROWN NORWAY RAT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FISCHER 344 RAT; LIVER; LYMPHOCYTE; MALE; NONHUMAN; PORTAL VEIN; RAT; SKIN; SOLID TUMOR; SPLEEN CELL; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COLONIC NEOPLASMS; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE TRANSFUSION; RATS; RATS, INBRED BN; RATS, INBRED F344; SKIN; SPLEEN; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; RATTUS; RATTUS NORVEGICUS;

EID: 33846919350     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0227     Document Type: Article

References (32)

1. Kushida T, Inaba M, Hisha H et al. Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 2001;97:3292-3299.
2. Ichioka N, Inaba M, Kushida T et al. Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells. STEM CELLS 2002;20:542-551.
3. Kaneda H, Adachi Y, Saito Y et al. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation. J Heart Lung Transpl 2005;24:1415-1423.
4. Taira M, Inaba M, Takada K et al. Treatment of streptozotocin-induced diabetes mellitus in rats by transplantation of islet cells from two major histocompatibility complex disparate rats in combination with intra bone marrow injection of allogeneic bone marrow cells. Transplantation 2005;79:680-687.
5. Wang J, Kimura T, Asada R et al. SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood 2003;101:2924-2931.
6. Slavin S, Morecki S, Weiss L et al. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 2002;11:265-276.
7. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501-1508.
8. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
9. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99:4234-4236.
10. Ueno NT, Rondon G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986-993.
11. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044-2049.
12. Zetterquist H, Hentschke P, Thorne A et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:1161-1166.
13. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2002;20:603- 606.
14. Helg C, Starobinski M, Jeannet M et al. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998;29:301-313.
15. Nakamura K, Inaba M, Sugiura K et al. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intrabone marrow bone marrow transplantation plus donor lymphocyte infusion. STEM CELLS 2004;22:125-134.
16. Suzuki Y, Adachi Y, Minamino K et al. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion. STEM CELLS 2005;23:365-370.
17. Topal B, Roskams T, Fevery J et al. Aggregated colon cancer cells have a higher metastatic efficiency in the liver compared with nonaggregated cells: an experimental study. J Surg Res 2003;112:31-37.
18. Tanaka K, Shimada H, Matsuo K et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650-659.
19. Minagawa M, Makuuchi M, Torzilli G et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000;231:487-499.
20. Kemeny N, Garay CA, Gurtler J et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2005;23:4753-4761.
21. Barkholt L, Danielsson R, Calissendorff B et al. Indium-111-labeled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004;78:697-703.
22. Thomas ED, Lochte HL, Lu WC et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491-496.
23. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-2024.
24. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. Blood 1989;73:1720-1728.
25. Tsukada N, Kobata T, Aizawa Y et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999;93:2738-2747.
26. Hattori K, Hirano T, Miyajima H et al. Metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Br J Haematol 1999;105:303-312.
27. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
28. Yokoyama WM, Seaman WE. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 1993;11:613-635.
29. Lanier LL. NK cell receptor. Annu Rev Immunol 1998;16:359-393.
30. Chen LK, Tourvieille B, Burns GF et al. Interferon: a cytotoxic T lymphocyte differentiation. Eur J Immunol 1986;16:767-770.
31. Johnson BD, Dagher N, Stankowski WC et al. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. Biol Blood Marrow Transplant 2001;11:589-595.
32. Blanc KL, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.